High dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapy

总结 研究专家（PAR-19-291） 在资深科学家佐尔坦·科尼亚博士的监督下，哈佛大学的研究人员和工作人员 医学院系统药理学实验室（LSP）将有助于细胞和组织成像 U2 C和U 54计划赠款的分析 基于LSP的研究者将进行基于组织的循环免疫荧光（t-CyCIF）方法 HMS在研究者提供的FFPE人类和小鼠皮肤样本上开发， 共同定义和验证抗体，以染色皮肤发育，炎症， 黑色素瘤进展和肿瘤微环境，并将分享正在开发的技术 为了进一步推进t-CyCIF方法（例如，切换到六通道成像，使用寡聚修饰的 抗体作为检测试剂，原位杂交或测序方法的组合）。的 LSP将处理t-CyCIF图像，提供定量细胞和组织水平的分析和帮助 分发高分辨率多路复用图像作为疾病病理学图谱的一部分。 Pisa将与PI Lian，Murphy，LeBoeuf，Haigis，Aster一起准备手稿，撰写报告 并根据PAR-19-291的要求与项目团队的其他成员合作。

Summary Grant: Research Specialist (PAR-19-291) Under the supervision of senior scientist Zoltan Maliga PhD, investigators and staff at the Harvard Medical School Laboratory of Systems Pharmacology (LSP) will contribute to cell and tissue imaging and analysis for U2C and U54 program grants LSP-based investigators will perform the tissue-based cyclic immunofluorescence (t-CyCIF) method developed at HMS on FFPE human and mouse skin samples provided by investigators and will work together to define and validate antibodies to stain biomarkers of skin development, inflammation, melanoma progression and tumor microenvironment and will share technologies under development to further advance the t-CyCIF method (e.g. switch to six-channel imaging, use of oligo-modified antibodies as detection reagents, combination of in situ hybridization or sequencing methods). The LSP will process t-CyCIF images, provide quantitative cell and tissue-level analysis and help distribute high-resolution multiplexed images as part of a disease pathology atlas. Maliga will work with PIs Lian, Murphy, LeBoeuf, Haigis, Aster to prepare manuscripts, write reports for the NIH and collaborate with other members of the project teams as required the by PAR-19-291.